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Abstract
In contrast to earlier studies which have used modelling to perform cost-effectiveness analy-
sis, this study links data from a randomised controlled trial with register data from nationwide
registries to reveal new evidence on costs, effectiveness, and cost-effectiveness of orga-
nised mass prostate-cancer screening based on prostate-specific antigen (PSA) testing.
Cost-effectiveness analyses were conducted with individual-level data on health-care costs
from comprehensive registers and register data on real-world effectiveness from the two
arms of the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC), follow-
ing 80,149 men from 1996 through 2015. The study examines cost-effectiveness in terms of
overall mortality and, in addition, in terms of diagnosed men’s mortality from prostate cancer
and mortality with but not from prostate cancer. Neither arm of the FinRSPC was clearly
more cost-effective in analysis in terms of overall mortality. Organised screening in the
FinRSPC could be considered cost-effective in terms of deaths from prostate cancer: avert-
ing just over one death per 1000 men screened. However, even with an estimated incre-
mental cost-effectiveness ratio of below 20,000€ per death avoided, this result should not
be considered in isolation. This is because mass screening in this trial also resulted in
increases in death with, but not from, prostate cancer: with over five additional deaths per
1000 men screened. Analysis of real-world data from the FinRSPC reveals new evidence of
the comparative effectiveness of PSA-based screening after 20 years of follow-up, suggest-
ing the possibility of higher mortality, as well as higher healthcare costs, for screening-arm
men who have been diagnosed with prostate cancer but who do not die from it. These find-
ings should be corroborated or contradicted by similar analyses using data from other trials,
in order to reveal if more diagnosed men have also died in the screening arms of other trials
of mass screening for prostate cancer.
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Introduction
There has been a wide range of evidence published on the effectiveness of systematic prostate-
specific-antigen–based screening in reducing prostate-cancer mortality [1–4]; however, associ-
ated estimates of costs and cost-effectiveness from real-world data have received much less
attention [5, 6]. Organised mass screening based on prostate-specific antigen (PSA) testing
potentially offers systematic early detection of aggressive prostate cancer at a curable stage and
thereby reduction of mortality [7]. However, the PSA test is not specific for cancer, as
increased PSA levels can equally indicate benign changes in the prostate, so the PSA test has
the potential to lead to harmful overtreatment [8]. Of course, questions extend beyond the
clinical realm: policy-level ones can be asked, about what PSA-based organised screening
might “cost” in relation to the “benefits” produced [9, 10]. Such relationships between costs
and effectiveness (i.e., economic efficiency) are often described through some form of cost-
effectiveness analysis (CEA) [11, 12]. While modelling-based CEA can provide useful informa-
tion, its results typically are highly dependent on both the data and the assumptions used,
which may sometimes be flawed or inaccurate [13, 14]. The need for assumptions can be mini-
mised and the data quality maximised by drawing conclusions directly from the results of a
pragmatic randomised controlled trial; we take this approach here, benefiting, e.g., from Fin-
land’s well established statutory health-care registries [15–17].
In light of the above considerations, a CEA was conducted with the primary aim of provid-
ing empirical estimates of some of the relationships between costs and effects of PSA screening
from the Finnish Randomised Study of Screening for Prostate Cancer (FinRSPC) after 20
years of the trial, using intention-to-screen analysis of health-care costs, mortality, and cost-
effectiveness.
Materials and methods
The FinRSPC
The complete age-based cohort for the FinRSPC was selected by staff at the Finnish population
registry and consists of all men born in 1929–1944 residing in the Helsinki or Tampere region
and alive on the date of randomisation (January 1 of each year from 1996 through 1999, a total
of 80,458 men were randomised). Those men randomised to the screening arm were systemat-
ically invited for organised tests (serum PSA determination) at a local clinic, while those in the
control arm received no such invitation as part of the trial. Three screening rounds were
arranged, at four-year intervals, with men above 71 years of age no longer invited. Serum PSA
was used for the primary screening test, with a cutoff of 4 ng/mL and ancillary testing for men
with PSA 3.0–3.9 (digital rectal examination in 1996–1997, free/total PSA ratio from 1997
onwards). Randomisation occurred before consent, i.e., in order to prevent self-selection
biases all men in the target age cohorts were randomised to one of the two arms without their
consent being sought, this was undertaken in full accordance with Finnish legislation at that
time. Follow-up started on January 1 in the year of randomisation and ended at death, upon
emigration, or on the common closing dates for analyses of both costs and effectiveness
(December 31, 2012–2015).
Register-data permissions and sources
The collection of data for this research was approved by the relevant Institutional Review
Boards: by the Finnish data-protection authority, by the National Institute for Health and Wel-
fare (THL), by approval from Statistics Finland (TK-53-1330-18), and by the Ethics Commit-
tees of the participating university-hospital districts. The need for consent from the men
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assigned to the trial was waived by a ruling from THL for the current register-based study
(Official decision number: THL/36/5.05.00/2009). Data were obtained from several registries
and entered in the FinRSPC database, using each man’s unique Finnish personal identity code
as the key for deterministic record linkage. Cancer cases were identified from the Finnish Can-
cer Registry (FCR), causes of death from Statistics Finland; episodes of hospital care from the
THL-maintained Care Register for Health Care (CRHC), and prescription-medicine reim-
bursements from the nationwide register (PMRR) maintained by the Social Insurance Institu-
tion of Finland. The PMRR contains information on the exact costs of outpatient prescription
medications paid by the healthcare sector in Finland. The CRHC is a comprehensive national
register which covers inpatient stays in, and outpatient visits to, hospitals. To classify and
identify resource use, we used the Finnish version of the Nordic Diagnosis Related Group
(NordDRG) -system [18]. Identifiable individual-level data cannot be shared publicly because
of Finnish legislation governing the protection of personal data. The data underlying the
results presented in the study can be obtained from the relevant Finnish authorities for
researchers who meet the criteria for access to confidential data. The funding organisations
did not play a role in the study design, data collection and analysis, decision to publish, or
preparation of the manuscript and only provided financial support in the form of authors’ sala-
ries and/or research materials. Fimlab Laboratories provided support in the form of a salary
for PK, but did not have any additional role in the study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Costs
Our CEA follows a healthcare-sector perspective using register-based costs; utilising individ-
ual-level data on publicly-provided secondary and tertiary health-care visits and stays for men
in the FinRSPC during the 20-year trial. In addition, the PMRR provides, to the nearest cent
(¢), the costs of outpatient prescription medications paid by the Social Insurance Institution of
Finland. For costs of secondary and tertiary care we used the most applicable NordDRG cost
weights (in euros), which the THL had gathered from Finnish hospitals, for both inpatient and
outpatient costs. The cost of the screening intervention itself was estimated by the FCR to cost
approximately 50 euros per screen (including organisation of invitations, drawing of the blood
sample, and PSA determinations but not any diagnostic evaluations, since the costs of diagnos-
tic tests are captured in our other cost estimates). All results are rounded to the nearest 100
euros to yield a level of precision suitable for comparative estimates of cost and cost-effective-
ness. Our base case analysis uses a discount rate of 3% per annum [19], and all euro amounts
were adjusted using the most appropriate price indices available from Statistics Finland. Fur-
ther details about these data sources and costs, as well as about the study design and trial regis-
tration have been provided in earlier FinRSPC or European Randomised Study of Screening
for Prostate Cancer (ERSPC) publications ([3, 5, 20] or [2]).
Analyses
The register data available on both costs and effects were analysed in accordance with the
intention-to-screen principle; that is, they were examined in accordance with the initial trial-
arm assignment. We used mortality as the measure of effectiveness, because no other register-
based effectiveness data were available (e.g., on health-related quality of life) [20]. All follow-
up is truncated at 17 years, with men who were randomised on January 1 1996 were followed
up until December 2012, whereas, e.g., men who were randomised on January 1 1999 were fol-
lowed up until December 2015. All tests of statistical significance are two sided, with Cox pro-
portional hazards regression used in the mortality analysis. Our CEA calculates incremental
CEA of PSA mass screening combining RCT and register data
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cost-effectiveness ratios (ICERs) by means of the data from the FinRSPC and national registers
on costs and effects [21]. Our health-economic approach focuses on differences in mortality,
including comparisons of the numbers of men dying between the two arms [19]. These health-
economic comparisons are reported in line with current standards, with the primary result
reported here being the overall ICER for the FinRSPC in terms of overall mortality [13], with
additional CEA analysis for two subgroups, firstly for men who died from prostate cancer and,
secondly, for men who died with, but not from prostate cancer [22]. All data handling and
analysis, including the merging of data from different registers, was performed using Stata
[23].
Results
In all, 31,867 men were assigned to the screening arm and 48,282 to the control arm, with
3,788 men in the screening arm (11.9%) and 5,050 men in the control arm (10.5%) being diag-
nosed with prostate cancer, respectively (Fig 1 [24]). Data on both costs and effectiveness were
recorded in the registers used in our study for 31,740 men in the screening arm (100%) and for
48,075 men in the control arm (100%). However, no cost records were found for 127 men in
the screening arm and 207 men in the control arm, including one man in the screening arm
who was diagnosed with and subsequently died of prostate cancer.
After 20 years of the trial, no statistically significant differences were observed between the
arms in terms of the estimated average health-care costs of all men (Table 1). Although average
costs for the 792 men who died of prostate cancer were around 10% higher in the screening
arm (not statistically significant), there were negligible differences in total costs between the
arms, since relatively few men died from prostate cancer in the screening arm. While average
Fig 1. Enrollment and health-related outcomes.
https://doi.org/10.1371/journal.pone.0224479.g001
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costs for the 1,610 men who died with but not from prostate cancer were approximately 5%
lower in the screening arm (not statistically significant), a small substantive increase in total
health-care costs for this subgroup was observed in the screening arm, as the rightmost column
in Table 1 shows. This is because more men in this arm, i.e., a higher percentage of men in the
screening arm, died with prostate cancer but not from it.
There was no statistically-significant difference in all-cause mortality (hazard ratio (HR) =
1.006, 95% confidence interval [CI], 0.98 to 1.03; P = 0.625) (Fig 2, Panel (A)). However,
among diagnosed men there was a reduction in prostate-cancer-specific death in the screening
arm: HR = 0.78, 95% CI, 0.68 to 0.90; P = 0.001 (Fig 2, Panel (B)). In addition, non-prostate-
cancer mortality for men diagnosed with prostate cancer was higher in the screening arm than
in the control arm: HR = 1.16, 95% CI, 1.05 to 1.27; P = 0.004 (Fig 2, Panel (C)). This increase
in the rate of non-prostate-cancer mortality for men diagnosed with prostate cancer in the
screening arm, seems to be most pronounced over five years after diagnosis (as Fig 2, Panel
(C) shows). Overall, differences in mean health-care costs and mean effectiveness for diag-
nosed men between the trial arms were relatively small with regard to both prostate-cancer
mortality and non-prostate-cancer mortality, with relatively high standard error (Table 2).
Our primary CEA produced a ICER which shows there was a health-related harm at less
cost. This primary CEA result is presented in Fig 3, Panel (A), and shows that 95% confidence
intervals are not able to be defined due to the uncertainty surrounding this estimate. Although
not statistically significant, after 20 years, the impact of the FinRSPC equates to just under two
additional deaths overall for every 1,000 men in the screening arm, with negligible savings in
health-care costs. This finding reflects approximately 63 more deaths overall in the screening
arm, which in turn reflects the negative contribution of approximately 136 more deaths
observed in the screening arm for men diagnosed with prostate cancer, after having adjusted
for the difference in size of the trial arms (Figs 1 and 2 and Table 2). Therefore, the ICER esti-
mated for the FinRSPC overall, can be expressed qualitatively as a statistically non-significant
reduction in costs accompanied by a statistically non-significant increase in the number of
deaths (Table 2).
The estimated ICER for men diagnosed with, and who died of, prostate cancer, is 19,400€
per prostate-cancer death averted. This reflects the 38 or so fewer deaths from prostate cancer
Table 1. Comparisons and statistical tests of the real-world health-care cost estimates. Results comparing trial arms during the 17-year follow-up.
Estimated all-cause health-care
costs (register-based)
N in control
arm
Mean in
control arm
N in screening
arm
Mean in
screening arm
Difference between
means
(standard error)
Two-sided t-
test
Difference† in total
costs
(in millions)
All men 48,075 €37,800 31,740 €37,600 -€200
(€400)
p = 0.65 -€5.3
Men not diagnosed with prostate
cancer
43,025 €36,100 27,953 €35,600 -€500
(€400)
p = 0.26 -€29.2
Men diagnosed with prostate cancer 5,050 €38,800 3,787 €39,300 €400
(€1,100)
p = 0.64 €23.9
Men who have survived with a
prostate cancer diagnosis
3,372 €46,300 2,524 €46,700 €300
(€1,100)
p = 0.76 €14.7
Men who died with, but not from,
prostate cancer
865 €62,400 745 €60,000 -€2,400
(€3,100)
p = 0.43 €9.7
Men who have died of prostate
cancer
500 €63,600 291 €68,500 €5,000
(€4,700)
p = 0.29 -€0.5
† = Differences are calculated as total costs in screening arm minus total costs in control arm and adjusted to take account of the relative size of the trial arms (rounded
to the nearest hundred thousand euros).
https://doi.org/10.1371/journal.pone.0224479.t001
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being observed in the screening arm after 20 years of the FinRSPC. However, only if a deci-
sion-maker’s willingness to pay per ‘prostate cancer death averted’ is over 120,000€ could the
screening arm of the FinRSPC be considered ‘cost-effective’ at conventional levels of statistical
significance (Fig 3, Panel (B)).
Fig 2. Nelson–Aalen estimates of risk of dying, from point of randomisation. Panel (A): Death from any cause,
during follow-up, by trial arm. Panel (B): Death from prostate cancer, for men diagnosed during follow-up, by trial
arm. Panel (C): Death with, but not from, prostate cancer, for men diagnosed during follow-up, by trial arm.
https://doi.org/10.1371/journal.pone.0224479.g002
CEA of PSA mass screening combining RCT and register data
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The analysis of cost-effectiveness above suggests a need to report on one further CEA too,
this one focusing on death from other causes than prostate cancer among men diagnosed with
prostate cancer (Fig 3, Panel (C)). This secondary analysis reports estimated cost-effectiveness
for the men diagnosed with prostate cancer, 174 more of whom perished in the screening arm
from causes other than prostate cancer, i.e., just over five additional deaths per 1000 men
screened. Fig 3, Panel (C) also reflects the likelihood that these additional deaths also come at a
cost in terms of health-care (of around 20,000€ per additional death).
Discussion
We examined the costs, effectiveness, and cost-effectiveness connected with a large popula-
tion-based comparative-effectiveness trial of organised PSA screening for prostate cancer. Tak-
ing each of these elements in turn, firstly, costs; in terms of mean health-care costs, we found
no indications of statistically-significant differences overall. However, such differences may
not be discernible due to the extensive heterogeneity observed in the trial participants’ utilisa-
tion of health-care services; i.e., extremely high health-care costs for some men in the trial
reduced the mean estimates’ ability to fully describe the cost impact [5, 25]. For example, aver-
age and total overall costs for men not diagnosed with prostate cancer were, somewhat surpris-
ingly, somewhat lower in the screening arm, even though men in the screening arm were
attributed the additional cost of screening (Table 2). This may suggest differences in health-
Table 2. Comparisons between the screening and control arms. Register-based health-care cost estimates, observed effectiveness and incremental cost-effectiveness
ratios, after 17 years of follow-up.
Control arm Screening arm Differences
(screening arm—control arm)
Incremental cost-
effectiveness ratio
(ICER)
Mean cost
in euros
Mean effect
(percentage of
deaths�)
Mean cost
in euros
Mean effect
(percentage of
deaths�)
in mean
cost in
euros
in mean effect
(percentage of
deaths†)
in number of
deaths averted‡
Point estimate
[effectiveness measure]
All men in the trial, using the effectiveness measure of deaths from any cause:
Mean
(total)
37,800 0.327 37,600 0.329 -100 0.001 -63 reduction in costs and
increase in deaths§
[death from any cause](standard
error)
(300) (0.002) (300) (0.003) (400)¶ (0.001)¶
Men diagnosed with prostate cancer, using the effectiveness measure of deaths from prostate cancer:
Mean
(total)
38,800 0.010 39,300 0.009 400 -0.02 38 19,400€k
[death from prostate
cancer](standard
error)
(600) (<0.001) (600) (<0.001) (900)¶ (0.006)
Men diagnosed with prostate cancer, using the effectiveness measure of cause of death something other than prostate cancer:
Mean
(total)
38,800 0.018 39,300 0.023 400 0.02 -174 increase in costs and
increase in deaths#
[death with, but not
from, prostate cancer]
(standard
error)
(600) (<0.001) (600) (<0.001) (900)¶ (0.008)¶
† = percentages expressed as decimals;
‡ = adjusted to take account of the relative size of the trial arms (rounded to the nearest integer);
§ = a 95% confidence interval is not able to be defined due to the uncertainty surrounding this estimate (see Fig 2, Panel (A));
¶ = bootstrap standard error;
k = an increase in mean costs (not statistically significant), and a statistically-significant increase in deaths averted (see Fig 2, Panel (B));
# = an increase in mean costs (not statistically significant) and a statistically-significant reduction in deaths averted, i.e., a statistically significant increase in deaths (see
Fig 2, Panel (C)).
https://doi.org/10.1371/journal.pone.0224479.t002
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Fig 3. Scatterplots of bootstrap replications of incremental cost-effectiveness ratios in terms of the number of
deaths. Panel (A): Estimates of incremental cost-effectiveness ratios in terms of death from any cause (for all men in
the trial). Panel (B): Estimates of incremental cost-effectiveness ratios in terms of death from prostate cancer (for men
diagnosed with prostate cancer). Panel (C): Estimates of incremental cost-effectiveness ratios in terms of death from
causes other than prostate cancer (for men diagnosed with prostate cancer).
https://doi.org/10.1371/journal.pone.0224479.g003
CEA of PSA mass screening combining RCT and register data
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care costs in our study may have more to do with random fluctuations or outliers in health-
care costs than screening itself. Of course, ideally the time horizon necessary for a comprehen-
sive cost-effectiveness analysis would be one that is long enough for all relevant costs (and out-
comes) to manifest (see, e.g., [26] or [19]). However, our analyses did not attempt to make
predictions about future costs or survival for the trial population, as robust methods were not
available to extrapolate from the health-care costs and mortality effects observed for men in
the FinRSPC who have already died, to those who may die in the coming years [27]. One fur-
ther reason for not extrapolating data beyond the within-trial horizon, is that the follow-up
period of the trial covered an expanse of time that witnessed many changes in prostate-cancer
treatment protocols.
Secondly, effectiveness, in exploratory mortality analyses prompted by our CEA findings in
terms of all-cause mortality and prostate-cancer mortality, we also evaluated comparative
effectiveness in terms of non-prostate-cancer mortality among the men diagnosed with pros-
tate cancer. We undertook these secondary analyses because it was apparent from our other
analysis results that, although on average prostate-cancer mortality was lower in the screening
arm among men diagnosed with the disease, all-cause mortality was higher in the screening
arm overall (even though this latter result was not statistically significant). To determine
whether or not our CEA findings in terms of all-cause mortality were due to chance and given
that the main impact of screening is, a priori, likely to be upon men diagnosed with prostate
cancer, we undertook further analyses of mortality among men diagnosed with prostate can-
cer. The above secondary analyses are not, of course, undertaken in full accordance with the
intention-to-screen (ITS) principle, however, three results reported in Fig 1, which do use the
ITS principle, should be noted. The first result of note is that, relative to the control arm, on
average 13% more men were diagnosed with prostate cancer in the screening arm (11.9% ver-
sus 10.5%). The second result of note is that, relative to the control arm, on average 13% less
men died from prostate cancer in the screening arm (0.9% versus 1.0%). The third result of
note in Fig 1 and, perhaps, the most important one here is that, relative to the control arm, on
average 27% more men in the screening arm died with, but not from, prostate cancer (2.3%
versus 1.8% in the control arm). A partial explanation for the result that, relative to the control
arm, on average 27% more men in the screening arm died with, but not from, prostate cancer,
could be related to overdiagnosis; with 13% more men on average diagnosed in the screening
arm, relative to the control arm. Such a ‘labelling’ effect could plausibly account for approxi-
mately half of the observed additional non-prostate cancer deaths in diagnosed men. A second
plausible explanation could be linked to competing causes of death; if more men are on aver-
age spared from death from prostate cancer due to PSA mass screening they may die of other
causes. However, analysis using a proxy for survival time–i.e., the follow-up time in each arm–
as the outcome measure (instead of number of deaths) also revealed an overall decrease in ‘sur-
vival time’ in the screening arm, for men diagnosed with prostate cancer. Put together, how-
ever, even the possible explanations listed above would still only seem to partially explain the
finding of higher mortality for screening-arm men who have been diagnosed with prostate
cancer but who do not die from it.
Although increased cardiovascular mortality due to endocrine therapy or the fear or stig-
matization associated with cancer diagnosis may play some role in our findings about non-
prostate-cancer mortality in men diagnosed with prostate cancer, such explanations remain
only speculations as to why more men in the screening arm died with prostate cancer but not
from it. In addition, we were not able to identify any single specific cause of death (or groups
of causes of death), such as deaths related to intentional self-harm, or other underlying differ-
ences between the arms, which could explain these mortality differences. The most marked
increases in non-prostate-cancer mortality were among those men in the screening arm with
CEA of PSA mass screening combining RCT and register data
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Tumor-Node-Metastasis -stage T1c cancers at diagnosis (i.e., impalpable cancers detectable
only by PSA testing [28]). Although our data suggest mid-level socioeconomic status may have
been associated with an increase in non-prostate-cancer mortality when men were diagnosed
with prostate cancer at any other than stage than stage T1c, these findings were not statistically
significant. Possibly due to the relatively small number of observed deaths at this stage, such
adjustments for socioeconomic status had minimal material impact on the differences between
the arms in terms of mortality among men with prostate cancer. Further explanatory analysis
is beyond the scope of this exploratory study.
Thirdly, we turn to the results relating to the cost-effectiveness of organised screening in
the FinRSPC, which varied according to the outcome measure used. We present three ICERs:
there was negligible impact of mass screening in the FinRSPC in terms of death from any
cause in all men, (what can be interpreted as) a positive impact for death from prostate cancer
in diagnosed men, and (what can be interpreted as) a negative impact for death with, but not
from, prostate cancer in diagnosed men. Sensitivity analysis showed that using a discount rate
of 5% and 1% does not result in major changes in the differences in costs or cost-effectiveness
between the two arms in any of these analyses. In their assessment of the cost-effectiveness of
screening, epidemiological studies have focused mainly on disease-specific mortality [2, 29,
30], often to the exclusion of any other effects on mortality [31]. In contrast to earlier CEAs
[32–36] our approach to health-economic evaluation considers not merely prostate-cancer
mortality; but characterizes all-cause mortality too, along with non-prostate-cancer mortality
in men diagnosed with prostate cancer. One potential pitfall in modelling cost-effectiveness in
a manner which does not adequately question the underlying epidemiology is that, accord-
ingly, any errors in the choice of outcome measures may be compounded in the act of model-
ling. If the choice of outcome measure is restricted by epidemiological convention this may
obscure relevant effects of the intervention, resulting in models neglecting to include a poten-
tially relevant health state, such as non-prostate-cancer mortality in men diagnosed with pros-
tate cancer. Incorporating all potentially important mortality impacts should be seen as central
in any health-economic evaluation [37].
The interpretation of incremental cost-effectiveness ratios is not a straightforward matter,
as the process of interpretation is typically specific to both the ICER’s content and the deci-
sion-making context in question. In the field of health-economic evaluation, a cost-effective-
ness ratio usually represents some indicator of the amount of health gained divided by some
estimate of the financial costs associated with that estimated ‘health’ gain. Only relatively infre-
quently, as in the secondary analysis presented here, does the cost-effectiveness ratio represent
some indicator of the amount of health lost divided by some estimate of the financial costs of
that estimated ‘health’ lost. When we report that, for men diagnosed with prostate cancer, the
estimated health-care cost per additional death is around 20,000€, this means that the data sug-
gests the trial was economically efficient at increasing non-prostate-cancer mortality for those
men. It should be clear from the results presented here that cost-effectiveness ratios can con-
tain or omit a wide range of factors. For this reason, understanding the content of each incre-
mental cost-effectiveness ratio is important when they are interpreted, for example, how well
costs and health effects are measured and analysed, and what costs and effects are, or are not,
included in the analysis. In Table 3 we set out the main research assumptions and key compo-
nents which underpin the health-economic evaluation of the FinRSPC.
In practice, interpretation of cost-effectiveness information requires understanding of the
components and qualities of that information [39]. Table 3 is intended to provide a useful
starting point for interpretation of the information about costs, effects and cost-effectiveness
provided by our study [40]. Interpretation of CEA results is also usually influenced by the
interplay between the decision-making context and the specific information provided by the
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Table 3. Main assumptions. Key elements of the health-economic evaluation of the FinRSPC.
A) Key elements of the analysis related to the FinRSPC:
strengths • Assignment to the trial arms occurred without prior consent (but with the permission of the
authorities)
• The men randomised represented the whole target population of the Tampere and Helsinki areas
during the period, i.e., all registered male citizens of the selected age groups were included
• Long-term register-based follow-up was available for practically all men (>99.9%)
limitations • Neither Finnish registries or the trial database includes consistent follow-up of either many of the
possible health-related impacts, or some of the costs, associated with prostate-cancer screening
• The FinRSPC is limited by its context, e.g.:
• clinical practice today may be quite different to that of the late 1990s
• PSA testing became more prevalent in the population over the period of the trial, which seems
likely to have had a significant effect on the impacts of the screening intervention [38]
• The long duration of follow-up may also mean that more influences unrelated to the screening trial
are reflected in its results, i.e., that there is more ‘noise’ in the data
• Clinical trials such as the FinRSPC typically can only provide robust information on average
treatment effects for the whole trial population. This is also the case for this trial, which practically
precludes robust analysis by, e.g., geographical- or age-related–subgroup
B) Key elements of the analysis related to costs:
strengths • The analysis uses well-established registers covering both use of hospital services (inpatient and
outpatient) as well as reimbursements for almost all outpatient prescription medications
• The registers provide almost complete coverage of these (hospital and prescription-medication) costs
for almost all men in the trial for almost the whole duration of the 20-year study
limitations • In principle, ideally all costs associated with PSA mass screening for prostate cancer and its
consequences might be included as part of a cost-effectiveness analysis, at least when attempting to
gauge the robustness of the results to the inclusion or omission of a range of cost items.
• Although information relating to primary care costs is typically included, such information was not
readily available from Finnish registers or the trial database, so is not included here
• Various cost drivers, such as costs to patients, costs which fall on the social-care budget, and costs of
lost productivity in the economy, were not included in our analyses
• Although the registers provide an identical source of data for men in both arms of the trial, and
although price indices and discount rates were applied uniformly in both arms, the register-based
cost estimates presented here are based on NordDRG cost weights, the cost estimates are, at best,
merely rough indicators of the magnitude of the true current costs which might be associated with
PSA mass screening for prostate cancer
C) Key elements of the analysis related to health-related outcomes:
strengths • The analysis presented here focuses on one of the most important and robust impacts related to
health outcomes, i.e., mortality
• The analysis uses data from well-established registries and precise cause-of-death registers with
practically complete coverage (at least for men who did not emigrate)
limitations • No direct measurement of health-related quality of life or patient satisfaction was possible using the
available register data
D) Key elements related to the cost-effectiveness analysis per se:
strengths • Each incremental cost-effectiveness ratio (ICER) presented looks at a different aspect of mortality,
together the three ICERs presented provide an a variety of useful indicators of the efficiency of mass
screening for prostate cancer in terms of the main impacts on mortality
• Although the cost drivers used in our analysis are limited in scope, as noted above (in section B) of
the table), the data provides almost complete coverage of two main costs: hospital care and
prescription medications
limitations • Each incremental cost-effectiveness ratio (ICER) presented looks at a different aspect of mortality,
none of the ICERs alone provide an all-encompassing indicator of the efficiency of organised PSA
mass screening for prostate cancer
• As noted above (in section C) of this table) our analysis does not incorporate health-related quality
of life considerations or considerations relating to patient satisfaction. For this reason the ICER
estimates presented here provide only a truncated representation of the efficiency of PSA mass
screening for prostate cancer and do not take into account important effects, e.g., on quality of life
https://doi.org/10.1371/journal.pone.0224479.t003
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incremental cost-effectiveness ratios in question. Therefore, judgment will typically be needed,
in every separate case and context, to gauge to what extent any estimated incremental cost-
effectiveness ratios provide an indication of ‘value’. Many elements of the chosen approach to
health-economic evaluation can markedly influence the results of cost-effectiveness analyses
[41]. When CEAs are based on a single randomised controlled trial, CEAs naturally are heavily
dependent on that source of information. Although randomised controlled trials are typically
seen as one of the best research methods to inform public health policy, it should be noted that
they do have their weaknesses [25, 42, 43]. Further details about the strengths and limitations
of our study will be set out below.
Strengths of the study
Our register-based cost-effectiveness analysis combines the power of a randomised controlled
trial with extensive follow-up via real-world data from comprehensive health-care registers. By
avoiding reliance on many of the assumptions typically necessary for modelling costs and out-
comes, our study represents a potentially significant application of CEA to improve the knowl-
edge base about organised screening for prostate cancer. Although numerous modelling-based
studies have been reported upon [32–36, 44], their estimates or forecasts typically do not pro-
ceed from data alone, with a frequent cascading effect wherein cost estimates are based on pre-
vious estimates of outcomes. Our results can be regarded as a groundbreaking contrast, in that
this is the first report on CEA based on real-world data derived from one study of PSA mass
screening. The men in the FinRSPC, i.e., in the Finnish arm of the ERSPC, were a complete
age cohort of the men in and around two main Finnish conurbations, Helsinki and Tampere.
The men were assigned to the two arms before randomisation, thus minimising problems
associated with selection to either group. Although the FinRSPC does not provide a perfectly
valid assessment of organised screening versus no screening, it likely provides a potentially
valid assessment of organised screening versus current clinical practice. The contamination by
opportunistic PSA-testing experienced during this trial is more likely to be generalizable to
current clinical practice than would ‘no screening’, by providing evidence of the likely impact
of organised screening over and above opportunistic testing [19]. In addition, the data over the
20 years of the trial (with 17-year median follow-up time), from fairly comprehensive data on
health-care costs and on effectiveness (in terms of mortality), help in obtaining potentially gen-
eralizable cost-effectiveness estimates, which realistically account for the diluting effects of
contamination.
Truncation of the follow-up at 17 years was undertaken to limit our analysis to only the
most robust data, because as age cohorts were selected from the population the on January 1 of
each year from 1996 through 1999, analysis without truncation would mean that follow-up
beyond 17 years would only be possible for fewer and fewer men each year until the maximum
of 20 years of follow-up. Truncation in this study produces more conservative results, with
analysis using all available data producing both larger effect sizes and more statistically-signifi-
cant associations.
Another strength of our study lies in its ability to inform current and future choices of suit-
able metrics for effectiveness [45]. For instance, our finding that over the 20 years of the
FinRSPC trial, mortality from causes other than prostate cancer among diagnosed men
increased in the screening arm has potentially significant implications for future research. Our
analysis likely provides a useful building block in that its findings could be input for testing
existing cost-effectiveness models’ sensitivity to new information, which has been shown to be
useful elsewhere [46]. In addition, similar analyses from comparable trials of organised screen-
ing could provide illuminating corroboration or contradiction of the findings presented here,
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because we are not aware of any other published analyses of mortality from causes other than
prostate cancer among diagnosed men in trials of PSA mass screening for prostate cancer [47].
Limitations of the study
As set out in parts of Table 3, this study is limited in scope for a number of reasons, e.g., that
no direct analysis of health-related quality of life or patient satisfaction was possible using the
available register data [48]. The estimates from a pragmatic trial in Finland presented here are
not necessarily indicative or representative of the impacts of organised PSA screening likely in
other health-care systems. Indeed, these estimates are unlikely to represent exact health-care
costs, effectiveness (in terms of mortality), or cost-effectiveness in other settings. However, this
is unavoidable for any pragmatic long-term, real-world study. The generalizability of our anal-
ysis to other settings is dependent on how well the manner of implementing the screening
intervention and subsequent care pathways in the FinRSPC can be generalized and also on
contextual elements such as the treatment patterns and the relative homogeneity of the
FinRSPC participants (the vast majority being Finnish and Caucasian). More generally, the
health-care system in which the trial took place (in the largely publicly-funded Finnish health-
care system) may limit generalizability. Despite these limitations, this trial of comparative
effectiveness does represent an important source of evidence, which can be used to supplement
earlier evidence from modelling studies. Of course, the authors acknowledge that, just as
modelling-based CEA depends on assumptions that may sometimes be flawed or inaccurate,
the relevance of empirical CEA to a wider population or time horizon also depends on
assumptions that may sometimes be flawed or inaccurate. In addition, all our results should be
interpreted in consideration of the likelihood of high levels of contamination in the control
arm [49], since most of the men in the control arm had a PSA test at some point in the trial
and the cumulative incidence of T1c cancers was, for example, only approximately 20% higher
in the screening arm than in the control arm. Although almost 75% of men in the screening
arm of the FinRSPC participated in the organised screening, we cannot know exactly which
men underwent non-systematic screening, i.e., opportunistic testing [38]. Further, the results
presented here for the subgroups of men diagnosed with prostate cancer are not necessarily
causally linked to randomisation, they are the result of randomisation followed by diagnosis,
so the intention-to-screen-analytic comparison between the arms is uncertain in this respect
[25]. However, the results of the intention-to-screen analysis show mortality effects of similar
magnitude to those in the subgroup analysis presented here. It should also be noted here that
health-economic evaluations are information-intensive in their input requirements and that
their use often suffers from a lack of appropriate information [50], especially as pathways to
health are quite complex [51]. For example, the main costs analysed were from secondary and
tertiary care, so various cost drivers, such as costs of lost productivity to the economy, costs of
primary-care treatment, and costs due to social care, were not considered. One of these, pri-
mary-care costs, were not included in our study as data were not available from registers for
the majority of the follow-up period (except to the extent that prescription medication use, as
part of primary care, was covered). However, we are not aware of any strong reason why pri-
mary care costs would differ substantially between the groups when, e.g., there were no major
differences in the costs of secondary or tertiary care. One further limitation (or, conversely,
potential strength), is that our study employed a fixed time horizon, setting it apart from many
model-based studies, which vary the time horizon modelled. On the other hand, models that
attempt to estimate “lifetime” costs and effectiveness typically rely on assumptions that could
seem out of place in light of the findings presented here, especially since we cannot know with
any certainty which direction the impacts of PSA screening will take next.
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Conclusion
Our primary analyses showed no major difference in overall health-care costs or in overall
mortality within the 17 years of follow-up. However, in further analysis, relatively minor
reductions in prostate-cancer mortality at the expense of increased costs in the screening arm
were found, but these may be outweighed by an increase in mortality from other causes for
men diagnosed with prostate cancer in the screening arm. Our analysis could be usefully sup-
ported or contradicted by similar analyses using data from comparable trials of mass screen-
ing. Longer-term follow-up may also allow more robust conclusions as to the balance of the
benefits and harms of introducing organised PSA mass screening.
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